# Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

> **NCT03991403** · PHASE3 · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 228 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab(Tecentriq)
- **DRUG:** Pemetrexed
- **DRUG:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin or cisplatin

## Key facts

- **NCT ID:** NCT03991403
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-27
- **Primary completion:** 2023-03-11
- **Final completion:** 2024-03-11
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2023-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03991403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03991403, "Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03991403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*